CoreCap Advisors’s CRISPR Therapeutics CRSP Stock Holding History

CoreCap Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.4K	Hold	99	–	–	﹤0.01%	2269
2026 Q1	$4.71K	Sell	99 -19	-16%	-$1K	﹤0.01%	2185
2025 Q4	$6.19K	Hold	118	–	–	﹤0.01%	2123
2025 Q3	$7.65K	Sell	118 -22	-16%	-$1.26K	﹤0.01%	2049
2025 Q2	$6.81K	Hold	140	–	–	﹤0.01%	2023
2025 Q1	$4.76K	Buy	140 +34	+32%	+$1.44K	﹤0.01%	2109
2024 Q4	$4.17K	Sell	106 -137	-56%	-$6.47K	﹤0.01%	2012
2024 Q3	$11.4K	Hold	243	–	–	﹤0.01%	1751
2024 Q2	$13.1K	Hold	243	–	–	﹤0.01%	1006
2024 Q1	$16.6K	Buy	+243	New	+$17.4K	﹤0.01%	1564
2022 Q4	$2.15K	Buy	+53	New	+$2.81K	﹤0.01%	1926
2022 Q3	–	Sell	-95	Closed	-$6K	–	850
2022 Q2	$6K	Buy	+95	New	+$5.58K	﹤0.01%	1605
2022 Q1	–	Sell	-42	Closed	-$3K	–	859
2021 Q4	$3K	Buy	+42	New	+$3.67K	﹤0.01%	1860

Other funds holding CRSP

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

WETS

Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BIP

Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

BAM

Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

CoreCap Advisors's CRSP Position: Q2 2026 in Review

CoreCap Advisors held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 99 shares worth $5.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

CoreCap Advisors first reported a position in CRSP in Q4 2021 and has held it in 13 quarters since. The position peaked at $16.6K in Q1 2024. 62 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

CoreCap Advisors held 99 shares of CRISPR Therapeutics worth $5.4K as of Q2 2026.
CoreCap Advisors left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2269 holding.
CoreCap Advisors first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 13 quarters since.
CoreCap Advisors's CRISPR Therapeutics position peaked at $16.6K in Q1 2024.
62 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.